FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205183913> ?p ?o ?g. }

• W4205183913 endingPage "S44" @default.
• W4205183913 startingPage "S43" @default.
• W4205183913 abstract "To assess the cost-effectiveness of polatuzumab in combination with bendamustine and rituximab (BR) compared to BR in the treatment of patients with relapsed/ refractory (R/R) diffuse large B-cell lymphoma (DLBC), in the Portuguese setting. A partitioned survival model including progression-free, progressed disease and death health states was used to estimate the cost-effectiveness of polatuzumab in combination with BR, using data from the GO29365, a phase Ib/II, open-label trial. Utility weights by health state were obtained from published literature. Portuguese-specific disease management resource use was based on a panel of clinical experts and on Portuguese diagnosis-related group microdata. The main sources for unit costs were national legislation and official drug cost databases. The analysis was conducted from the National Health Service perspective, assuming a lifetime horizon and a 4% discount rate for both costs and effects. Deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of Results. Polatuzumab+BR increases average life expectancy by 1.08 life years (LY) or 0.78 quality adjusted life years (QALY), with estimated incremental cost-effectiveness ratios (ICER) of 53,978€/LY and 74,560€/QALY. Considering just second-line treatment, polatuzumab+BR increases average life expectancy by 2.18 LY or 1.57 QALY allowing an ICER of 31,231€/LY or 43,408€/QALY. For third-line, polatuzumab+BR increases average life expectancy by 0.78 LY or 0.56 QALY, increasing the ICER to 73,483€/LY or 101,937€/QALY. Deterministic sensitivity analyses show that results are robust to most scenarios but sensitive to modelling options, vial sharing and time horizon. Treatment with polatuzumab in combination with BR showed an incremental effectiveness both in terms of LY and QALY compared to BR alone. The cost-effectiveness model of polatuzumab in combination with BR in patients with untreated R/R-DLBC was considered valid to support a reimbursement decision in the Portuguese setting." @default.
• W4205183913 created "2022-01-26" @default.
• W4205183913 creator A5023278475 @default.
• W4205183913 creator A5026021779 @default.
• W4205183913 creator A5053459841 @default.
• W4205183913 creator A5061548681 @default.
• W4205183913 creator A5062590251 @default.
• W4205183913 creator A5082183816 @default.
• W4205183913 date "2022-01-01" @default.
• W4205183913 modified "2023-09-26" @default.
• W4205183913 title "POSA56 A Cost-Effectiveness Analysis of Polatuzumab in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Portugal" @default.
• W4205183913 doi "https://doi.org/10.1016/j.jval.2021.11.201" @default.
• W4205183913 hasPublicationYear "2022" @default.
• W4205183913 type Work @default.
• W4205183913 citedByCount "0" @default.
• W4205183913 crossrefType "journal-article" @default.
• W4205183913 hasAuthorship W4205183913A5023278475 @default.
• W4205183913 hasAuthorship W4205183913A5026021779 @default.
• W4205183913 hasAuthorship W4205183913A5053459841 @default.
• W4205183913 hasAuthorship W4205183913A5061548681 @default.
• W4205183913 hasAuthorship W4205183913A5062590251 @default.
• W4205183913 hasAuthorship W4205183913A5082183816 @default.
• W4205183913 hasBestOaLocation W42051839131 @default.
• W4205183913 hasConcept C112930515 @default.
• W4205183913 hasConcept C126322002 @default.
• W4205183913 hasConcept C133925201 @default.
• W4205183913 hasConcept C144024400 @default.
• W4205183913 hasConcept C149923435 @default.
• W4205183913 hasConcept C187212893 @default.
• W4205183913 hasConcept C2779338263 @default.
• W4205183913 hasConcept C2780653079 @default.
• W4205183913 hasConcept C2781442060 @default.
• W4205183913 hasConcept C2908647359 @default.
• W4205183913 hasConcept C3019080777 @default.
• W4205183913 hasConcept C64332521 @default.
• W4205183913 hasConcept C71924100 @default.
• W4205183913 hasConcept C99454951 @default.
• W4205183913 hasConceptScore W4205183913C112930515 @default.
• W4205183913 hasConceptScore W4205183913C126322002 @default.
• W4205183913 hasConceptScore W4205183913C133925201 @default.
• W4205183913 hasConceptScore W4205183913C144024400 @default.
• W4205183913 hasConceptScore W4205183913C149923435 @default.
• W4205183913 hasConceptScore W4205183913C187212893 @default.
• W4205183913 hasConceptScore W4205183913C2779338263 @default.
• W4205183913 hasConceptScore W4205183913C2780653079 @default.
• W4205183913 hasConceptScore W4205183913C2781442060 @default.
• W4205183913 hasConceptScore W4205183913C2908647359 @default.
• W4205183913 hasConceptScore W4205183913C3019080777 @default.
• W4205183913 hasConceptScore W4205183913C64332521 @default.
• W4205183913 hasConceptScore W4205183913C71924100 @default.
• W4205183913 hasConceptScore W4205183913C99454951 @default.
• W4205183913 hasIssue "1" @default.
• W4205183913 hasLocation W42051839131 @default.
• W4205183913 hasOpenAccess W4205183913 @default.
• W4205183913 hasPrimaryLocation W42051839131 @default.
• W4205183913 hasRelatedWork W1497351677 @default.
• W4205183913 hasRelatedWork W1979692821 @default.
• W4205183913 hasRelatedWork W2052625449 @default.
• W4205183913 hasRelatedWork W2341149492 @default.
• W4205183913 hasRelatedWork W2576026972 @default.
• W4205183913 hasRelatedWork W2766497960 @default.
• W4205183913 hasRelatedWork W2794975738 @default.
• W4205183913 hasRelatedWork W3125858761 @default.
• W4205183913 hasRelatedWork W4205588450 @default.
• W4205183913 hasRelatedWork W4247414321 @default.
• W4205183913 hasVolume "25" @default.
• W4205183913 isParatext "false" @default.
• W4205183913 isRetracted "false" @default.
• W4205183913 workType "article" @default.